Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the PROSPER clinical trial investigating the role of enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) as presented at ASCO GU 2021 and considers whether PSA is an accurate marker for survival

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the design and outcomes of the ACIS study investigating the combination of apalutamide and abiraterone plus prednisone (AAP) versus abiraterone plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides perspective on the role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have failed prior therapies

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the prostate-specific membrane antigen (PSMA) lutetium and outcomes from the VISION clinical trial presented at ASCO GU 2021

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers the role of precision medicine in prostate cancer and the clinical significance of the PROFOUND trial from the 2021 Genitourinary Cancers Symposium

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, regarding the preliminary analysis of combination belzutifan (an oral HIF-2α inhibitor) and cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, offers a message for prostate cancer patients regarding the clinical developments from ASCO GU 2021

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, shares a message for patients regarding clinical progress in bladder cancer as seen at the 2021 Genitourinary Cancers Symposium

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, shares perspective on the role of PD-L1 testing in previously untreated, locally advanced or metastatic urothelial carcinoma (mUC) as seen in the Phase III IMvigor130 study presented at ASCO GU 2021

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, offers opinion on the use of nivolumab as an adjuvant treatment for muscle-invasive urothelial carcinoma as a result of CheckMate 274

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...